Mogroside IVe can inhibit the proliferation of HT29 and Hep-2 cells in culture and in xenografted mice in a dose-dependent manner, which is accompanied by the upregulation of tumor suppressor p53, and downregulation of matrix metallopeptidase 9 (MMP-9) and phosphorylated extracellular signal-regulated kinases (ERK)1/2.